Sergei Vadimovich Tsaregorodtsev

Mr. Sergei Vadimovich Tsaregorodtsev

Pharmacology, Moscow State University of Medicine and Dentistry, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
JGJulia Galeeva
Julia Galeeva
DFDmitry E. Fedorov
Dmitry E. Fedorov
ESElizaveta Starikova
Elizaveta Starikova
AMAleksander Manolov
Aleksander Manolov
APAlexander V. Pavlenko
Alexander V. Pavlenko
EIElena Ilina
Elena Ilina
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global healthcare, underscoring the importance of exploring the virus’s effects on infected individuals beyond treatments and vaccines. Notably, recent findings suggest that SARS-CoV-2 can infect the gut, thereby altering the gut microbiota. This study aimed to analyze the gut microbiota composition differences between COVID-19 patients experiencing mild and severe symptoms. We conducted 16S rRNA metagenomic sequencing on fecal samples from 49 mild and 43 severe COVID-19 cases upon hospital admission. Our analysis identified a differential abundance of specific bacterial species associated with the severity of the disease. Severely affected patients showed an association with Enterococcus faecium, Akkermansia muciniphila, and others, while milder cases were linked to Faecalibacterium prausnitzii, Alistipes putredinis, Blautia faecis, and additional species. Furthermore, a network analysis using SPIEC-EASI indicated keystone taxa and highlighted structural differences in bacterial connectivity, with a notable disruption in the severe group. Our study highlights the diverse impacts of SARS-CoV-2 on the gut microbiome among both mild and severe COVID-19 patients, showcasing a spectrum of microbial responses to the virus. Importantly, these findings align, to some extent, with observations from other studies on COVID-19 gut microbiomes, despite variations in methodologies. The findings from this study, based on retrospective data, establish a foundation for future prospective research to confirm the role of the gut microbiome as a predictive biomarker for the severity of COVID-19.

28 August 2025 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
IMIgor V. Maev
Igor V. Maev
DADmitrii Nikolaevich Andreev
Dmitrii Nikolaevich Andreev
RSR I Shaburov
R I Shaburov
AZAndrey Vladimirovich Zaborovsky
Andrey Vladimirovich Zaborovsky
AFAlexey Fomenko
Alexey Fomenko
AVA V Vychkin
A V Vychkin
Aim. To evaluate the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 versus rifaximin monotherapy in patients with small intestinal bacterial overgrowth (SIBO) associated with long-term proton pump inhibitor (PPI) use. Materials and methods. A prospective comparative study with two parallel groups was conducted. Eligible patients were those on continuous long-term PPI therapy ( 3 months) with confirmed SIBO. SIBO was diagnosed in all patients using a lactulose Hydrogen/Methane Breath Test (HMBT). Symptom severity was assessed using the validated "7 × 7" Questionnaire, and Quality of Life (QoL) was evaluated using the SF-36 Health Status Survey. Enrolled patients were randomized into two groups based on a 7-day treatment regimen: Group 1 received rifaximin (400 mg twice daily); Group 2 received rifaximin (400 mg twice daily) plus the probiotic Saccharomyces boulardii CNCM I-745 (Enterol® drug product, Biocodex, France; 500 mg twice daily). SIBO eradication was confirmed via repeat lactulose HMBT, and symptom severity/QoL were reassessed 4 weeks after treatment completion. Results. 108 patients were enrolled (mean age 38.7 ± 8.9 years; 65.7% female). Mean PPI treatment duration at enrollment was 4.81 months (95% confidence interval 4.15–5.46). At 4-week follow-up, repeat lactulose HMBT showed SIBO persistence in 41.5% of Group 1 (n = 22/53) versus 21.8% in Group 2 (n = 12/55; p = 0.038). Statistically significant resolution of diarrhea was observed only in Group 2 (p = 0.033). The final median "7 × 7" Questionnaire score was significantly lower in Group 2 (p = 0.0010). Both groups showed significant trends toward QoL improvement on the SF-36 survey. Conclusion. This prospective comparative study demonstrates that combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 appears more effective than rifaximin monotherapy for SIBO eradication, symptom regression, and QoL improvement in patients with PPI-associated SIBO.

17 March 2023 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
OKO. A. Kulikov
O. A. Kulikov
DYD. V. Yunina
D. V. Yunina
VAV. P. Ageev
V. P. Ageev
VSV. I. Shlyapkina
V. I. Shlyapkina
IAI. S. Avdyushkina
I. S. Avdyushkina
NPN. A. Pyataev
N. A. Pyataev

19 July 2023 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
DYDina V. Yunina
Dina V. Yunina
VAValentin P. Ageev
Valentin P. Ageev
AZAndrey Vladimirovich Zaborovsky
Andrey Vladimirovich Zaborovsky
LTLarisa A. Tararina
Larisa A. Tararina
STSergei Vadimovich Tsaregorodtsev
Sergei Vadimovich Tsaregorodtsev
OKOleg Alexandrovich Kulikov
Oleg Alexandrovich Kulikov
Introduction: The study of the pharmacokinetics of glucocorticosteroids is often required to solve fundamental and applied tasks of pharmacology. HPLC methods based on ultraviolet detection are attractive due to their availability, but their sensitivity is low enough to study in vivo kinetics. In this study, we propose a method for the determination of dexamethasone in biological objects, based on the use of HPLC with UV detection and having sufficient sensitivity to determine the drug in biological media (blood and periarticular tissues). Materials and methods: Extraction of dexamethasone from biosamples was carried out by liquid-liquid extraction with acetone in an acidic medium using atenolol as an internal standard. The analysis was carried out on a Kromasil-100 C18 column. A mixture of methanol with phosphate buffer in the ratio 50÷50, pH=5.6 was used as the mobile phase. Detector - UV, wavelength - 254 nm. The LLOQ of the method was 50 ng/mL; the calibration curve demonstrated linearity in the con-centration range of 50-1000 ng/mL.The method was used to detect the medicinal product in peri-synovial tissues of rats with an autoimmune arthritis model. Results: This study demonstrated that intraarticular injection of the liposomal form of dexamethasone, compared with its water-soluble form, allows maintaining the active concentration of the product in the joint and periarticular tissues for a longer time, which creates prerequisites for enhancing its therapeutic effect. Conclusion: The proposed method provides a sensitive and specific approach for measuring dexamethasone in biological samples, such as blood and periarticular tissues. Preliminary findings indicate that the liposomal form of dexamethasone may exhibit better pharmacokinetic properties than the water-soluble form, which could lead to improved therapeutic outcomes.

22 December 2025 in Medicine and Biotechnology
Verified
Journal Article
Open access
PDF file
DSDmitry O. Semikov
Dmitry O. Semikov
IMIgor V. Maev
Igor V. Maev
AZAndrey Vladimirovich Zaborovsky
Andrey Vladimirovich Zaborovsky
APAnna E. Pashkovskaya
Anna E. Pashkovskaya
AKAndrey V. Kulikov
Andrey V. Kulikov
ЦВЦарегородцев Сергей Вадимович
Царегородцев Сергей Вадимович
Introduction. Hepatic disorders constitute a significant global health challenge, underscoring the critical need for effective therapeutic strategies. Hepatoprotective agents play a pivotal role in management; however, their efficacy is frequently constrained by pharmacokinetic limitations. The objective of this review is to provide a systematic analysis of contemporary approaches to hepatoprotection, encompassing an evaluation of existing pharmacological classes, combination treatment regimens, and emerging directions, such as the application of nanotechnology to enhance the bioavailability and therapeutic potential of active pharmaceutical ingredients. Materials and methods. A review and analysis of contemporary scientific literature pertaining to liver disease epidemiology, the classification of hepatoprotective agents, and the application of nanotechnology for the enhancement of their bioavailability was conducted. The literature search was performed across the PubMed, Springer Link, and eLibrary databases, with selection criteria limited to relevant publications from the past decade. Results. Despite the diversity of hepatoprotector classes with distinct mechanisms of action, their clinical efficacy is often constrained by low bioavailability. Analysis reveals that the most promising strategy to overcome these limitations is the application of nanotechnology to create targeted drug delivery systems. Discussion and conclusion. Current evidence indicates a lack of a universally effective hepatoprotective agent, with many combination regimens requiring further investigation. There is a demonstrated need both to optimize existing therapeutics through nano-engineering approaches and to continue the search for novel pharmacologically active compounds.

11 May 2024 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
OYO. O. Yanushevich
O. O. Yanushevich
NKN. I. Krikheli
N. I. Krikheli
IMIgor V. Maev
Igor V. Maev
AZAndrey Vladimirovich Zaborovsky
Andrey Vladimirovich Zaborovsky
OLOleg Levchenko
Oleg Levchenko
ORO. V. Rudneva
O. V. Rudneva
Relevance. The COVID-19 pandemic caused by the SARS-CoV-2 virus has demonstrated the critical importance of understanding the mechanisms of transmission and finding effective methods of prevention. Particular attention has been paid to the role of oral hygiene, as the oral cavity serves as a major route of transmission. Studies show that the composition of the oral microbiota can influence the course and outcome of COVID-19 disease. Therefore, there is a need to study the effects of oral antiseptics on the microbiome, which may offer new opportunities for the prevention and treatment of this disease.Objective. The aim of this study is to evaluate the effectiveness of the oral cleansing foam «Parodontol PROF» in reducing the pathogenic microflora of the oral cavity in patients with COVID-19 and to assess its effect on the risk of secondary infections.Materials and methods. The study was conducted on the basis of the Clinical Medical Centre «Kuskovo» of Russian University of Medicine. It included 450 patients with a confirmed diagnosis of COVID-19. The participants were divided into two groups: the test group used oral cleansing foam, while the control group used no additional oral hygiene. Comparative analyses of the taxonomic composition of the oropharyngeal microbiota and dental plaque before and after the use of the cleansing foam were performed.Results. The study showed that patients who regularly used the cleansing foam «Parodontol PROF» had a significant decrease in the representation of pathogens, including Mycoplasma, and an increase in the number of beneficial commensals such as Lactococcus and Lactobacillus. These changes indicate the potential efficacy of this product to improve oral hygiene and reduce the risk of secondary infections.Conclusion. The study supports the hypothesis that improving oral hygiene with specialised antiseptic agents, such as a cleansing foam, may help to reduce pathogenic microflora in the oral cavity in patients with COVID-19. This, in turn, may reduce the risk of pathogen migration into the lower respiratory tract and the development of secondary infections. The findings emphasise the importance of further research in this area and the development of comprehensive approaches to oral hygiene management in the context of infectious diseases.